WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility

WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility

WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany. The permit successfully demonstrates for the first time that Premier Quality together with Record Speed WuXi Biologics consistently delivered in China can also be applied in global countries.